Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of siponimod: A systematic review.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Sept 2022

Díaz-Villamarín Xando, Piñar-Morales Raquel, Barrero-Hernández Francisco Javier, Antúnez-Rodríguez Alba, Cabeza-Barrera José, Morón-Romero Rocío

Abstract excerpt

Multiple sclerosis is a chronic inflammatory neurological disease, and siponimod (Mayzent) is the first oral treatment option for adult patients with secondary progressive multiple sclerosis. We performed a systematic review of the pharmacogenetics of Siponimod, and we found that (430 C>T; rs1799853) and CYP2C9 * 3 (1075 A>C; rs1057910), both translated no-function alleles, have been related to a lower metabolism...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azetidines
Share to Benzyl Compounds
Share to Cytochrome P-450 CYP2C9
Share to Genotype
Share to Pharmacogenetics

Source

Identifiers

PMID: 36076616
DOI: 10.1016/j.biopha.2022.113536

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of siponimod: A systematic review.PMID 36076616Read ↗

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.Semantic proximity Read ↗

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.Semantic proximity Read ↗

Frequency of pharmacogenomic variants affecting safety and efficacy of immunomodulators and biologics in a South Asian population from Sri Lanka.Semantic proximity Read ↗

Major implications of single nucleotide polymorphisms in human carboxylesterase 1 on substrate bioavailability.Semantic proximity Read ↗

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.Semantic proximity Read ↗

The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.Semantic proximity Read ↗

Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.Semantic proximity Read ↗

Pharmacogenetics of multiple sclerosisSemantic proximity Read ↗

Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple SclerosisSemantic proximity Read ↗

An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effectsSemantic proximity Read ↗

CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.Semantic proximity Read ↗

Siponimod and CYP2C9 Allele Prevalence Among Blacks.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.